AZN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AstraZeneca is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows strong financial growth and analysts have generally positive ratings, the recent price decline, lack of strong technical signals, and mixed sentiment in the options market suggest waiting for a more favorable entry point.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 37.639, and the stock is trading near a key support level of 197.412. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the overall trend is weak due to recent price declines.
Hedge funds are significantly increasing their positions in AstraZeneca, with a 166.61% increase in buying activity over the last quarter. Analysts from Morgan Stanley and Citi highlight strong earnings growth potential and a robust product pipeline.
The stock has declined in the regular market (-1.99%) and post-market (-0.84%), indicating weak short-term sentiment. Additionally, Deutsche Bank maintains a Sell rating, and the MACD is signaling bearish momentum.
In Q4 2025, AstraZeneca reported a 4.11% YoY revenue increase to $15.5 billion. Net income surged 55.07% YoY to $2.33 billion, and EPS grew 55.21% YoY to 1.49. However, gross margin declined by 2.70% YoY to 78.89%.
Analyst sentiment is mixed but leans positive. Morgan Stanley and Citi have Buy or Overweight ratings, citing strong earnings growth and a robust pipeline. However, Deutsche Bank maintains a Sell rating, and Goldman Sachs recently removed the stock from its European Conviction List.
